Vol. 2 No. 8 (2026), Articles
Vol. 2 No. 8 (2026)

WHEN BACTERIA FIGHT BACK: UNDERSTANDING MULTIDRUG RESISTANCE AND ITS GENETIC ROOTS IN PATHOGENIC BACTERIA

Articles
Published 2026-05-07
Musthaq Ahmed Mohamed
Dr. Professor Department of Microbiology, Virology & Immunology Fergana Medical Institute of Public Health Fergana, Uzbekistan
PDF

Keywords

multidrug resistance; antibiotic resistance genes; horizontal gene transfer; mobile genetic elements; efflux pumps; beta-lactamase; ESKAPE pathogens; resistance mechanisms

Abstract

Background: Antibiotic resistance was once considered a distant threat; today it is a clinical reality reshaping how we treat even routine infections. Multidrug resistance (MDR)—defined as non-susceptibility to agents across three or more antibiotic categories—has taken hold in hospitals and communities worldwide, leaving clinicians with dangerously few options. Objective: This review explores the genetic machinery behind MDR, examining how bacteria acquire, store, and share resistance genes, and how those genes translate into the mechanisms that defeat our drugs. Methods: We searched Scopus, PubMed, and Web of Science for literature published between 2005 and 2024, prioritizing primary research and authoritative reviews on resistance genetics and mechanisms. Results: MDR arises through four principal strategies: enzymatic drug destruction, active drug expulsion via efflux pumps, alteration of the drug's binding target, and tightening of the bacterial membrane against drug entry. The genes driving these strategies—ranging from bla-family beta-lactamases to mcr colistin-resistance genes—travel efficiently between organisms on plasmids, transposons, and integrons. Conclusion: Addressing MDR demands more than new drugs; it requires an intimate understanding of how bacteria think genetically, because only then can we design interventions that are truly durable.

PDF

References

Cassini A, Hogberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and EEA in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56-66.

[2] O'Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Review on Antimicrobial Resistance. London: HM Government and Wellcome Trust; 2016.

[3] Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-1081.

[4] Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281.

[5] Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42-51.

[6] Bush K, Bradford PA. Beta-Lactams and beta-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6(8):a025247.

[7] Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005;41(Suppl 2):S120-S126.

[8] Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161-168.

[9] Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest. 2003;111(9):1265-1273.

[10] Carattoli A. Plasmids and the spread of resistance. Int J Med Microbiol. 2013;303(6-7):298-304.

[11] Gillings MR. Integrons: past, present, and future. Microbiol Mol Biol Rev. 2014;78(2):257-277.

[12] Garg N, Alam M, Bhattacharyya R, Bhatt D, Mitra DK, Bhattacharya G. Bacteriophage-mediated transduction of antimicrobial resistance genes. Front Microbiol. 2023;14:1221320.

[13] Wright GD. Bacterial resistance to antibiotics: enzymatic degradation and modification. Adv Drug Deliv Rev. 2005;57(10):1451-1470.

[14] Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother. 2005;56(1):20-51.

[15] Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic: a vision for applied use. Biochem Pharmacol. 2006;71(7):910-918.

[16] Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat. 2010;13(6):151-171.

[17] Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7(9):629-641.

[18] Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003;67(4):593-656.

[19] Russo TA, Marr CM. Hypervirulent Klebsiella pneumoniae. Clin Microbiol Rev. 2019;32(3):e00001-19.

[20] Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538-582.

[21] Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22(4):582-610.

[22] Werner G, Coque TM, Hammerum AM, et al. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill. 2008;13(47):19046.

[23] Hernandez A, Ruiz FM, Romero A, Martinez JL. The binding of triclosan to SmeT, the repressor of the smeDEF multidrug efflux pump of Stenotrophomonas maltophilia, induces antibiotic resistance. PLoS Pathog. 2011;7(6):e1002103.

[24] Lebeaux D, Ghigo JM, Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev. 2014;78(3):510-543.

[25] Hendriksen RS, Munk P, Njage P, et al. Global monitoring of antimicrobial resistance based on metagenomics analyses of urban sewage. Nat Commun. 2019;10(1):1124.

[26] Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318-327.